Literature DB >> 27246070

Vitamin D in corticosteroid-naïve and corticosteroid-treated Duchenne muscular dystrophy: what dose achieves optimal 25(OH) vitamin D levels?

Nahla Alshaikh1, Andreas Brunklaus1, Tracey Davis1, Stephanie A Robb1, Ros Quinlivan1, Pinki Munot1, Anna Sarkozy1, Francesco Muntoni1, Adnan Y Manzur1.   

Abstract

AIM: Assessment of the efficacy of vitamin D replenishment and maintenance doses required to attain optimal levels in boys with Duchenne muscular dystrophy (DMD).
METHOD: 25(OH)-vitamin D levels and concurrent vitamin D dosage were collected from retrospective case-note review of boys with DMD at the Dubowitz Neuromuscular Centre. Vitamin D levels were stratified as deficient at <25 nmol/L, insufficient at 25-49 nmol/L, adequate at 50-75 nmol/L and optimal at >75 nmol/L. RESULT: 617 vitamin D samples were available from 197 boys (range 2-18 years)-69% from individuals on corticosteroids. Vitamin D-naïve boys (154 samples) showed deficiency in 28%, insufficiency in 42%, adequate levels in 24% and optimal levels in 6%. The vitamin D-supplemented group (463 samples) was tested while on different maintenance/replenishment doses. Three-month replenishment of daily 3000 IU (23 samples) or 6000 IU (37 samples) achieved optimal levels in 52% and 84%, respectively. 182 samples taken on 400 IU revealed deficiency in 19 (10%), insufficiency in 84 (47%), adequate levels in 67 (37%) and optimal levels in 11 (6%). 97 samples taken on 800 IU showed deficiency in 2 (2%), insufficiency in 17 (17%), adequate levels in 56 (58%) and optimal levels in 22 (23%). 81 samples were on 1000 IU and 14 samples on 1500 IU, with optimal levels in 35 (43%) and 9 (64%), respectively. No toxic level was seen (highest level 230 nmol/L).
CONCLUSIONS: The prevalence of vitamin D deficiency and insufficiency in DMD is high. A 2-month replenishment regimen of 6000 IU and maintenance regimen of 1000-1500 IU/day was associated with optimal vitamin D levels. These data have important implications for optimising vitamin D dosing in DMD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  General Paediatrics; Neurology; Neuromuscular; Nutrition; Paediatric Practice

Mesh:

Substances:

Year:  2016        PMID: 27246070     DOI: 10.1136/archdischild-2015-308825

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  3 in total

Review 1.  Nutraceuticals and Their Potential to Treat Duchenne Muscular Dystrophy: Separating the Credible from the Conjecture.

Authors:  Keryn G Woodman; Chantal A Coles; Shireen R Lamandé; Jason D White
Journal:  Nutrients       Date:  2016-11-09       Impact factor: 5.717

2.  Bone Mineral Density Assessment by Quantitative Computed Tomography in Glucocorticoid-Treated Boys With Duchenne Muscular Dystrophy: A Linear Mixed-Effects Modeling Approach.

Authors:  Chuan Liu; Dan-Dan Yang; Lu Zhang; Xian-Gao Lei; Feng-Lin Jia; Yi Liao; Xi-Jian Chen; Gang Ning; Wen Luo; Hai-Bo Qu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-23       Impact factor: 5.555

3.  The relationship of bone mineral density and vitamin D levels with steroid use and ambulation in patients with Duchenne muscular dystrophy.

Authors:  Filiz Meryem Sertpoyraz; Bedile İrem Tiftikçioğlu
Journal:  Turk J Phys Med Rehabil       Date:  2019-08-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.